China SXT Pharmaceuticals Inc is a holding company mainly engaged in the research, development, manufacture, marketing and sales of Chinese traditional medicine products (TCMP). The Company sells different types of TCMP products, including Advanced TCMP and Regular TCMP. Advanced TCMP comprises of Directly-Oral-TCMP and After-Soaking-Oral TCMP. Regular TCMP is mainly for hospitals and drug stores for the treatment of various diseases or serving as dietary supplements. The Company sells its products under the brand Suxuantang.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
17/07/26	$2.450	-4.67%	14,671
16/07/26	$2.570	-0.39%	9,700
15/07/26	$2.580	+7.05%	8,639
14/07/26	$2.410	-5.49%	33,800
13/07/26	$2.550	0.00%	4,365

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Other stock markets 23:30:00 17/07/2026 +03			5-day change	1st Jan Change
2.450 ^USD	-4.67%		-3.92%	-98.98%

07-03	China SXT Pharmaceuticals, Inc. announced that it expects to receive $28.56 million in funding	CI
07-01	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2026	CI

Market Cap	78.93M 68.98M 63.65M 58.67M 111M 7.6B 113M 761M 299M 3.72B 296M 290M 12.82B	P/E 2025 *	-	P/E 2026	-0.18x
Enterprise Value	51.73M 45.21M 41.72M 38.45M 72.48M 4.98B 74.09M 499M 196M 2.44B 194M 190M 8.4B	EV / Sales 2025	9.81x	EV / Sales 2026	-22.6x
Free-Float	99%	Yield 2025 *	-	Yield 2026	-

07-03	China SXT Pharmaceuticals, Inc. announced that it expects to receive $28.56 million in funding	CI
07-01	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2026	CI
01-08	Top Midday Gainers	MT
01-01	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended September 30, 2025	CI
31/07/25	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2025	CI
28/03/25	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended September 30, 2024	CI
17/03/25	China Sxt Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Requirement	MT
24/01/25	China SXT Pharmaceuticals, Inc. Announces CEO Changes	CI
24/01/25	China SXT Pharmaceuticals, Inc. Announces Board and Committee Changes	CI
21/01/25	China SXT Pharmaceuticals, Inc. announced that it expects to receive $2.84 million in funding	CI
13/08/24	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024	CI
13/08/24	China SXT Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
13/05/24	China SXT Pharmaceuticals, Inc. announced that it has received $0.75 million in funding from Streeterville Capital, LLC	CI

07-01	China SXT Pharmaceuticals : Annual Report for Fiscal Year Ending March 31, 2026 (Form 20-F)	PU
03-24	China SXT Pharmaceuticals, Inc. Announces Share Re-classification	AQ
01-30	China SXT Pharmaceuticals, Inc. Announces Share Consolidation	AQ
01-15	CHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC INITIATIVE TO APPLY AI TECHNOLOGY ACROSS THE TCM SUPPLY CHAIN	AQ
01-14	Univest Securities, LLC Announces Closing of $10 Million Registered Direct Offering for its Client China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC)	AQ

China SXT Pharmaceuticals, Inc. Stock

Stocks

SXTC

VGG2161P1650

Pharmaceuticals

Valuation: China SXT Pharmaceuticals, Inc.

Chart: China SXT Pharmaceuticals, Inc.

Latest news : China SXT Pharmaceuticals, Inc.

Press Releases: China SXT Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: China SXT Pharmaceuticals, Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	-4.67%
1 week	-3.92%
Current month	+16.11%
1 month	+9.87%
3 months	+21.89%
6 months	-82.81%
Current year	-98.98%

1 week	2.2	2.73
1 month	1.89	2.93
Current year	1.25	1,046.98
1 year	1.25	1,046.98
3 years	1.25	11,249.94
5 years	1.25	935,981.28
10 years	1.25	1,000,000

Manager	Title	Age	Since
Sze Beng Lim CEO	Chief Executive Officer	-	20/01/2025
Feng Zhou CEO	Chief Executive Officer	34	04/07/2017
Xiaodong Pan DFI	Director of Finance/CFO	49	31/01/2022

Director	Title	Age	Since
Feng Zhou CHM	Chairman	34	04/07/2017
Jun Zheng BRD	Director/Board Member	49	31/12/2018
Xiaodong Ji BRD	Director/Board Member	57	22/05/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CHINA SXT PHARMACEUTICALS, INC.	-4.67%	-3.92%	-99.01%	-99.96%	78.93M
ELI LILLY AND COMPANY	+0.85%	-0.80%	+52.79%	+159.97%	1,051B
JOHNSON & JOHNSON	+1.23%	-1.53%	+54.58%	+59.41%	609B
ABBVIE INC.	+0.04%	+2.58%	+34.47%	+84.84%	450B
ROCHE HOLDING AG	-0.04%	+0.97%	+30.63%	+21.95%	330B
NOVARTIS AG	-0.82%	-0.58%	+35.29%	+36.18%	284B
ASTRAZENECA PLC	-0.21%	-0.32%	+22.85%	+17.52%	263B
NOVO NORDISK A/S	+0.91%	+2.42%	-19.14%	-39.82%	223B
AMGEN INC.	-1.42%	+0.80%	+24.27%	+57.85%	198B
GILEAD SCIENCES, INC.	-1.48%	+3.43%	+24.08%	+70.06%	167B
Average	-0.56%	+0.09%	+16.08%	+36.80%	357.51B
Weighted average by Cap.	+0.29%	+0.02%	+37.74%	+78.00%

	2025	2026
Net sales	1.74M 1.52M 1.4M 1.29M 2.44M 168M 2.49M 16.78M 6.6M 82.11M 6.54M 6.39M 283M	1.14M 995K 918K 846K 1.59M 110M 1.63M 10.97M 4.31M 53.68M 4.27M 4.18M 185M
Net income	-3.3M -2.89M -2.66M -2.46M -4.63M -318M -4.73M -31.84M -12.52M -156M -12.41M -12.13M -536M	-6.21M -5.42M -5M -4.61M -8.69M -598M -8.89M -59.81M -23.52M -293M -23.3M -22.79M -1.01B
Net Debt	-17.25M -15.08M -13.91M -12.82M -24.17M -1.66B -24.71M -166M -65.41M -814M -64.79M -63.37M -2.8B	-27.2M -23.77M -21.93M -20.22M -38.11M -2.62B -38.95M -262M -103M -1.28B -102M -99.91M -4.42B